Osteoporosis Approved Drugs
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Osteoporosis.
Found 12 Approved Drugs for Osteoporosis
Xgeva
Generic Name
Denosumab
Xgeva
Generic Name
Denosumab
Form: Injection
Method of administration: Subcutaneous
FDA approval date: June 05, 2010
Classification: RANK Ligand Inhibitor
Prolia is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture.
Alendronate
Brand Names
Binosto, Fosamax
Alendronate
Brand Names
Binosto, Fosamax
Form: Tablet, Solution
Method of administration: Oral
FDA approval date: February 06, 2008
Classification: Bisphosphonate
Alendronate sodium tablets are a bisphosphonate indicated for: Treatment and prevention of osteoporosis in postmenopausal women.
Forteo
Generic Name
Teriparatide
Forteo
Generic Name
Teriparatide
Form: Injection
Method of administration: Subcutaneous
FDA approval date: November 26, 2002
Classification: Parathyroid Hormone Analog
Teriparatide injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, teriparatide injection reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. Teriparatide injection is a parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )
Evista
Generic Name
Raloxifene
Evista
Generic Name
Raloxifene
Form: Tablet
Method of administration: Oral
FDA approval date: January 06, 1998
Classification: Estrogen Agonist/Antagonist
Raloxifene hydrochloride tablets are an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women.
Showing 1-5 of 12
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances